Skip to main content

Graves Disease (Diffuse Hyperplasia)

  • Chapter
  • First Online:
  • 3148 Accesses

Part of the book series: Atlas of Anatomic Pathology ((AAP))

Abstract

Graves disease, an autoimmune disorder, is the most common cause of hyperthyroidism. Graves disease is associated with antibodies against the thyrotropin receptor that stimulate the receptor and promote synthesis and secretion of thyroglobulin and follicular cell proliferation. Patients present with goiter and symptoms of hyperthyroidism, including anxiety, tachycardia, palpitations, tremor, heat sensitivity, and weight loss, and may develop ophthalmopathy and dermopathy. Patients may be treated symptomatically with β-blockers and with antithyroid medications (propothiouracil and methimazole), radioactive iodine, and surgery. Complications of untreated Graves disease are thyroid storm, muscle catabolism with myopathy, and bone catabolism with osteoporosis, among others. Graves disease occurs in 1 in 2,000 people in the United States. A study from Olmstead County, Minnesota, reports an incidence of 30 cases per 100,000 person years. Graves disease is more common in women than in men. There is a marked increase risk of Graves disease in the postpartum period. In men, Graves disease occurs at an older age and frequently is more severe and associated with greater ophthalmopathy. Graves disease occasionally occurs in children and has a high concordance in identical twins. Smoking is associated with an increased risk of Graves disease and Graves ophthalmopathy. Patients have elevated serum thyroxine and low thyroid-stimulating hormone levels. There is an association with HLA-B8 and DR3, and patients may have a familial predisposition to autoimmune disease, including thyroid disease. Thyroid carcinomas occasionally occur in thyroids involved by Graves disease. In a retrospective review of 61 thyroid carcinomas with concurrent Graves disease, 58 papillary carcinomas, 1 follicular carcinoma, 1 Hurthle cell carcinoma, and 1 medullary carcinoma were identified. Most (80 %) of the tumors were 1 cm or smaller. Incidental thyroid carcinomas are less prevalent in Graves disease than in multinodular goiter.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Furszyfer J, et al. Graves’ disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc. 1970;45(9):636–44.

    CAS  PubMed  Google Scholar 

  2. Balazs C, Stenszky V, Farid NR. Association between Graves’ ophthalmopathy and smoking. Lancet. 1990;336(8717):754.

    Article  CAS  PubMed  Google Scholar 

  3. Brandle M, et al. Medullary thyroid carcinoma in Graves’ disease. Clin Endocrinol. 1999;50(4):545–6.

    Article  CAS  Google Scholar 

  4. Chao TC, Lin JD, Chen MF. Surgical treatment of thyroid cancers with concurrent Graves disease. Ann Surg Oncol. 2004;11(4):407–12.

    Article  PubMed  Google Scholar 

  5. Pascual Corrales E, et al. Incidental differentiated thyroid carcinoma is less prevalent in Graves’ disease than in multinodular goiter. Endocrinol Nutr. 2012;59(3):169–73.

    Article  PubMed  Google Scholar 

  6. Erickson LA, et al. p27kip1 expression distinguishes papillary hyperplasia in Graves’ disease from papillary thyroid carcinoma. Mod Pathol. 2000;13(9):1014–9.

    Article  CAS  PubMed  Google Scholar 

  7. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14(1):55–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Erickson, L.A. (2014). Graves Disease (Diffuse Hyperplasia). In: Atlas of Endocrine Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0443-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0443-3_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0442-6

  • Online ISBN: 978-1-4939-0443-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics